Back to search results

YB-101 for Graves' Disease

This study is evaluating a drug called YB-101 for people with Graves' Disease. Researchers want to see how safe YB-101 is, how well your body tolerates it, and how it moves through your system. They also want to understand its effect on your thyroid function. To join, you must have a confirmed diagnosis of Graves' Disease, which means having specific antibodies called TRAbs. The study will compare YB-101 to a placebo (an inactive substance) over 24 weeks. Success would mean participants have normal thyroid hormone levels (FT3, FT4, TSH) and can stop taking their anti-thyroid drugs. The current status of this study is unclear, and it plans to enroll 232 participants.

Study design
This is an interventional study with a planned enrollment of 232 participants. It includes a blinded treatment period where you will receive either YB-101 or a placebo.
What's involved
You will have 34-39 in-clinic visits over approximately 40 weeks. You will receive YB-101 or placebo through injections under your skin.
Compensation
Not stated in the trial record.
Follow-up
Your safety and thyroid hormone levels will be measured at Baseline and Day 169.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07682896

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Recruiting
PHASE2Ages 18+InterventionalTreatment
Yarrow Bioscience, Inc.
~232 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:Experimental: YB-101Placebo YB-101

At a glance

Recruiting sites
17 of 30 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Measured over Baseline, Day 169
+1 more outcome measured

Conditions

Graves' Disease

Explore related trials

Graves DiseaseThyrotropin receptor

NCT07682896

Where you'd take part

This study runs at 30 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Clinical Research Site

    Tucson, Arizonano site contact published

    Not yet recruiting

  • Clinical Research Site

    Raleigh, North Carolinano site contact published

    Not yet recruiting

  • Clinical Research Site

    Dallas, Texasno site contact published

    Not yet recruiting

  • Site 100

    Amarillo, Texasno site contact published

    Recruiting

  • Site 101

    Humble, Texasno site contact published

    Recruiting

  • Site 103

    Sacramento, Californiano site contact published

    Not yet recruiting

  • Site 105

    Torrance, Californiano site contact published

    Not yet recruiting

  • Site 106

    Fort Worth, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Victoria Lacasse, MD
[email protected]
469-278-6161
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment
Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening

Exclusion

Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy
Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening
Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening
History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit
Pregnant or lactating women

What this trial measures

  • Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Baseline, Day 169
  • Proportion of participants with normal free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) who discontinued anti-thyroid drugs (ATDs), regardless of concomitant levothyroxine useBaseline, Day 169